IDEAYA Biosciences (IDYA) EV/EBITDA: History & Chart

IDEAYA Biosciences, Inc.(IDYA)

Biotechnology · South San Francisco, CA

$36.67-1.40 (-3.67%)

Delayed quote: Oct 6, 2026, 10:25 AM EDT

About IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.

South San Francisco, CA

145 employees

www.ideayabio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Yujiro S. Hata

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
IDEAYA Biosciences, Inc. (IDYA)	$3.49B	N/A	N/A	N/A	N/A
CareDx, Inc (CDNA)vs ›	$3.46B	199.71x	115.31x	72.49x	72.49x
Celcuity Inc. (CELC)vs ›	$3.45B	N/A	N/A	N/A	N/A
iRhythm Technologies, Inc. (IRTC)vs ›	$3.55B	288.49x	665.65x	665.65x	665.65x
Acadia Pharmaceuticals Inc. (ACAD)vs ›	$3.42B	31.56x	29.77x	69.20x	69.20x
Arcutis Biotherapeutics, Inc. (ARQT)vs ›	$3.04B	83.95x	355.62x	355.62x	355.62x
Denali Therapeutics Inc. (DNLI)vs ›	$3.03B	N/A	116.71x	116.71x	116.71x
Amylyx Pharmaceuticals, Inc. (AMLX)vs ›	$3.03B	N/A	9.21x	9.21x	9.21x
ICU Medical, Inc. (ICUI)vs ›	$3.95B	13.55x	16.01x	14.76x	19.10x
Enliven Therapeutics, Inc. (ELVN)vs ›	$2.99B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

IDEAYA Biosciences, Inc. (IDYA)

$3.49B

N/A

CareDx, Inc (CDNA)vs ›

$3.46B

199.71x

115.31x

72.49x